Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Infect Dis
    April 2026
  1. WARRIER L, Saito A, Graham JB, Swarts JL, et al
    Initiation of oral pre-exposure prophylaxis associated with changes in genital tract T cell phenotypes in women exposed to HIV.
    J Infect Dis. 2026 Apr 9:jiag204. doi: 10.1093.
    >> Share

    March 2026
  2. MANI M, Clipman SJ, Bailey JR, Sterling RK, et al
    Single-cell hepatitis B sequencing reveals distinct viral infection events consistent with superinfection.
    J Infect Dis. 2026 Mar 20:jiag181. doi: 10.1093.
    >> Share

    February 2026
  3. ENGEL N, Dumond JB, Kashuba ADM, Cottrell ML, et al
    Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention.
    J Infect Dis. 2026;233:257-260.
    >> Share

    December 2025
  4. MAKAROVA N, Singletary T, Peet MM, Kelley K, et al
    Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infection.
    J Infect Dis. 2025 Dec 4:jiaf611. doi: 10.1093.
    >> Share

  5. TEWARI SE, Hoffman R, Lockman S, Flanagan CF, et al
    Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness.
    J Infect Dis. 2025 Dec 1:jiaf521. doi: 10.1093.
    >> Share

    November 2025
  6. HUME SJ, Visvanathan K, Cheng K, Jackson K, et al
    Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.
    J Infect Dis. 2025 Nov 14:jiaf569. doi: 10.1093.
    >> Share

  7. HANSCOM B, Marzinke MA, Li X, Donnell D, et al
    Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083.
    J Infect Dis. 2025 Nov 5:jiaf561. doi: 10.1093.
    >> Share

    October 2025
  8. COX S, Andreatta K, Hendricks MR, Li J, et al
    Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies.
    J Infect Dis. 2025 Oct 24:jiaf533. doi: 10.1093.
    >> Share

  9. HIRANBURANA N, Sophonphan J, Kerr SJ, Ubolyam S, et al
    NAT2 polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living with HIV: Insights from a Pharmacogenetic-Pharmacokinetic Cohort Study.
    J Infect Dis. 2025 Oct 1:jiaf511. doi: 10.1093.
    >> Share

    August 2025
  10. LABARILE M, Schoepf IC, Pasin C, Oumelloul MA, et al
    Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study.
    J Infect Dis. 2025 Aug 27:jiaf438. doi: 10.1093.
    >> Share

    July 2025
  11. MOHAN H, Nguyen J, Yee A, Laurette EY, et al
    Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and Cabotegravir.
    J Infect Dis. 2025 Jul 15:jiaf362. doi: 10.1093.
    >> Share

    June 2025
  12. BAUERMEISTER JA, Arrington-Sanders R, Coleman-Lewis J, Bertagnolli LN, et al
    Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex with Men: The DREAM ATN Study (ATN 163).
    J Infect Dis. 2025 Jun 28:jiaf349. doi: 10.1093.
    >> Share

  13. PERAZZOLO S, Flexner CW, Stephen ZR, Acosta EP, et al
    Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement.
    J Infect Dis. 2025 Jun 24:jiaf319. doi: 10.1093.
    >> Share

  14. DESCHENES NM, Perez-Vargas J, Zhong Z, Thomas M, et al
    Functional and structural characterization of treatment-emergent nirmatrelvir resistance mutations at low frequencies in the main protease (Mpro) reveals a unique evolutionary route for SARS-CoV-2 to gain resistance.
    J Infect Dis. 2025 Jun 3:jiaf294. doi: 10.1093.
    >> Share

    May 2025
  15. ZHENG R, Fuchs EJ, Nimmagadda S, Rohan LC, et al
    Anal Sex and Tenofovir Douche Sequence Impacts Colorectal Distribution of HIV Surrogate and Douche (DREAM-02).
    J Infect Dis. 2025 May 31:jiaf286. doi: 10.1093.
    >> Share

    April 2025
  16. MUNOZ-MUELA E, Mejias-Trueba M, Serna-Gallego A, Saborido-Alconchel A, et al
    Mitochondrial disorders after 12 months of HIV-1 preexposure prophylaxis based on tenofovir disoproxil fumarate plus emtricitabine in healthy adults.
    J Infect Dis. 2025 Apr 1:jiaf156. doi: 10.1093.
    >> Share

    February 2025
  17. YOUNAS M, Gimenez S, Lin YL, Mettling C, et al
    GABA-induced monocytic reactive oxygen species impair CD4 restoration in treated HIV-1 adults.
    J Infect Dis. 2025 Feb 4:jiaf058. doi: 10.1093.
    >> Share

    October 2024
  18. TOBIN NH, Brooker SL, Li F, Coombs RW, et al
    Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women with HIV.
    J Infect Dis. 2024 Oct 31:jiae524. doi: 10.1093.
    >> Share

  19. TERRAULT NA, Sterling R, Lok AS, Ghany MG, et al
    HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
    J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093.
    >> Share

  20. BAILON L, Puertas MC, Garcia-Guerrero MC, Moraes-Cardoso I, et al
    Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.
    J Infect Dis. 2024 Oct 28:jiae530. doi: 10.1093.
    >> Share

    September 2024
  21. SRINIVASAN S, Richardson BA, Wallis JM, Fiedler TL, et al
    Vaginal Bacteria and Proinflammatory Host Immune Mediators as Biomarkers of Human Immunodeficiency Virus Acquisition Risk Among African Women.
    J Infect Dis. 2024 Sep 9:jiae406. doi: 10.1093.
    >> Share

  22. DE SCHEERDER MA, Degroote S, Delporte M, Kiselinova M, et al
    In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA).
    J Infect Dis. 2024 Sep 3:jiae405. doi: 10.1093.
    >> Share

    July 2024
  23. LANTZ A, Kiweewa Matovu F, Johnson R, Isingel E, et al
    Female genital tract host factors and tenofovir and lamivudine active metabolites.
    J Infect Dis. 2024 Jul 24:jiae372. doi: 10.1093.
    >> Share

  24. KURITZKES DR
    Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.
    J Infect Dis. 2024 Jul 8:jiae214. doi: 10.1093.
    >> Share

  25. ZHOU S, Long N, Rosenke K, Jarvis MA, et al
    Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
    J Infect Dis. 2024 Jul 8:jiae213. doi: 10.1093.
    >> Share

    June 2024
  26. WANG F, Rademeyer K, Namuju OC, Abdusalaamu K, et al
    Post-mortem analysis of dolutegravir, tenofovir, lamivudine and efavirenz penetration in multiple CNS compartments.
    J Infect Dis. 2024 Jun 20:jiae325. doi: 10.1093.
    >> Share

  27. JACOBSON DL, Crider KS, DeMarrais P, Brummel S, et al
    Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.
    J Infect Dis. 2024 Jun 15:jiae308. doi: 10.1093.
    >> Share

    May 2024
  28. MCCLUSKEY SM, Muyindike WR, Nanfuka V, Omoding D, et al
    Population Effectiveness of Dolutegravir Implementation in Uganda - A Prospective Observational Cohort Study (DISCO): 48-week Results.
    J Infect Dis. 2024 May 16:jiae260. doi: 10.1093.
    >> Share

  29. WU L, Kinuthia J, Anderson PL, Baeten JM, et al
    Drug concentrations in hair and dried blood spots as PrEP adherence metrics during pregnancy and postpartum.
    J Infect Dis. 2024 May 3:jiae208. doi: 10.1093.
    >> Share

    April 2024
  30. RIDDLER SA, Kelly CW, Hoesley CJ, Ho KS, et al
    A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
    J Infect Dis. 2024 Apr 24:jiae211. doi: 10.1093.
    >> Share

  31. BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al
    Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
    J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093.
    >> Share

    January 2024
  32. SCRIMIERI F, Bastian E, Smith M, Rehm CA, et al
    Transcriptionally-active "defective" HIV-1 proviruses and their association with immunological non-response to antiretroviral therapy.
    J Infect Dis. 2024 Jan 16:jiae009. doi: 10.1093.
    >> Share

    December 2023
  33. MAKAROVA N, Singletary T, Peet MM, Mitchell J, et al
    Extended post-exposure protection against vaginal SHIV infection with tenofovir alafenamide fumarate/elvitegravir inserts in macaques.
    J Infect Dis. 2023 Dec 22:jiad599. doi: 10.1093.
    >> Share

    November 2023
  34. WELD ED, McGowan I, Anton P, Fuchs EJ, et al
    Tenofovir Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, & Pharmacodynamics (DREAM 01).
    J Infect Dis. 2023 Nov 29:jiad535. doi: 10.1093.
    >> Share

  35. ZIVICH PN, Cole SR, Edwards JK, Glidden DV, et al
    HIV prevention among men who have sex with men: tenofovir alafenamide combination preexposure prophylaxis versus placebo.
    J Infect Dis. 2023 Nov 16:jiad507. doi: 10.1093.
    >> Share

    September 2023
  36. BUTT AA, Yan P, Shaikh OS, Talisa VB, et al
    Nirmatrelvir/ritonavir Use and Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19: A matched cohort study.
    J Infect Dis. 2023 Sep 15:jiad393. doi: 10.1093.
    >> Share

    August 2023
  37. PARASKEVIS D, Gkova M, Mellou K, Gerolymatos G, et al
    Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients.
    J Infect Dis. 2023 Aug 11:jiad324. doi: 10.1093.
    >> Share

  38. SCEVOLA S, Niubo J, Domingo P, Verdejo G, et al
    Decay of human immunodeficiency virus (HIV) RNA in seminal plasma and rectal fluid in treatment-naive adults starting antiretroviral therapy with dolutegravir plus lamivudine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Infect Dis. 2023 Aug 1:jiad304. doi: 10.1093.
    >> Share

    May 2023
  39. SCHWENKE JM, Thorball CW, Schoepf IC, Ryom L, et al
    Association of a Polygenic Risk Score with Osteoporosis in People Living with HIV: The Swiss HIV Cohort Study.
    J Infect Dis. 2023 May 24:jiad179. doi: 10.1093.
    >> Share

    December 2022
  40. DONNELLAN S, Pennington SH, Ruggiero A, Martinez-Rodriguez C, et al
    A quantitative method for the study of HIV-1 and Mycobacterium tuberculosis co-infection.
    J Infect Dis. 2022 Dec 20:jiac491. doi: 10.1093.
    >> Share

    October 2022
  41. JAO J, Sun S, Bonner LB, Legbedze J, et al
    Lower insulin sensitivity in newborns with in utero HIV and antiretroviral exposure who are uninfected in Botswana.
    J Infect Dis. 2022 Oct 14. pii: 6761332. doi: 10.1093.
    >> Share

  42. ESHLEMAN SH, Fogel JM, Halvas EK, Piwowar-Manning E, et al
    HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention.
    J Infect Dis. 2022 Oct 14. pii: 6761331. doi: 10.1093.
    >> Share

    September 2022
  43. SMITH MSR, Mohan H, Ajaykumar A, Hsieh AYY, et al
    Second-generation HIV integrase inhibitors induce differentiation dysregulation and exert toxic effects in human embryonic stem cell and mouse models.
    J Infect Dis. 2022 Sep 19. pii: 6704757. doi: 10.1093.
    >> Share

  44. AVERY RK, Prono MVD
    Bebtelovimab in the Real World: Promise and Fulfillment.
    J Infect Dis. 2022 Sep 17. pii: 6702587. doi: 10.1093.
    >> Share

  45. RAZONABLE RR, O'Horo JC, Hanson SN, Arndt RF, et al
    Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch.
    J Infect Dis. 2022 Sep 17. pii: 6702534. doi: 10.1093.
    >> Share

  46. HALL SA, Burns GS, Mooney BJ, Millen R, et al
    Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
    J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
    >> Share

    March 2022
  47. ESHLEMAN SH, Fogel JM, Piwowar-Manning E, Chau G, et al
    Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
    J Infect Dis. 2022 Mar 18. pii: 6549543. doi: 10.1093.
    >> Share

    August 2021
  48. PALICH R, Teyssou E, Sayon S, Abdi B, et al
    Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.
    J Infect Dis. 2021 Aug 20. pii: 6355381. doi: 10.1093.
    >> Share

    March 2021
  49. LOHMAN-PAYNE B, Koster J, Gabriel B, Chilengi R, et al
    Persistent Immune activation in HIV-Infected Pregnant Women Initiating cART Post Conception.
    J Infect Dis. 2021 Mar 29. pii: 6199840. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016